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Abstract. Chronic Lymphocytic Leukemia (CLL) are
in some cases stereotyped for immunoglobulin variants
in different populations, suggesting emergence of B cell
subsets following presentation of the same antigen. CLL
cells may originate from CD5+ na¨ıve cells and from CD5
memory cells. Gene expression studies characterized a
common cell of origin of the two clinical categories of
CLL; the unmutated aggressive type and the mutated
indolent type. The aim of this study was to investig-
ate the presence of CD5 positive B cells in the elderly
and their potential stimulation with exosomes derived
from tumor cells. The findings from this study is aimed
to create a model to identify instigating carcinomatous
factors that may stimulate B1 cells to transform into a
CLL-like model.
In this study we show that CD19+ cells (B cells) in
cord blood have a high expression of CD5. CD19/CD5
staining of blood samples from senior citizens showed
the presence of B cells which also express the CD5
marker, though at a lower expression when compared
to CLL cells (CD19+/CD5dim B cells). Measurement
of clonality using ń/κ flow cytometry staining show a
monoclonal origin of the human CD19+/CD5dimB cells.
Monoclonal B cell Lymphocytosis in the elderly is a
potential cell compartment that represents the origin
of B cell proliferative disorders. The origin of the B
cell proliferative disease requires antigen stimulation. A
preliminary experiment showed that sorted lymphocytes
can be stimulated by exosomes isolated from 2 cancer
cells lines, A549 (lung epithelial) and PC3 (prostate
cell line). In comparison with phytohaemagglutinin
(PHA) and phorbolmyristate acetate (PMA), known
lymphocyte stimulators, the exosomes stimulated the
proliferation of monocytic-like cells. Further charac-
terization is required to know the origin of these cells.
The result shows that one can speculate that exosomes
present cancer-derived antigens and stimulate cell pro-
liferation. Further studies are required to evaluate the
potential transformation capacity of cancer-derived exo-
somes. In addition, various cytokines were measured in
the sera of senior citizens to investigate a differential
release of cytokines in the presence or absence of the
CD19+/CD5dim B cells. Cytokines examined were not
significantly different between the 2 groups and further
evaluation of cytokine levels is required.
Keywords: CD5+ B cells, exosomes, CLL, lymphocyt-
osis
1 Introduction
Development of lymphoproliferative disorders have been
studied extensively, with a number of observations
that elicit interesting mechanisms that are still not
fully understood, such as the origin of subpopula-
tions of B cells expressing the CD5 marker. Lympho-
mas are lineage specific and proliferate and transform
into the specific sub-types reflecting the cell of ori-
gin (Caligaris-Cappio & Hamblin, 1999; Stevenson &
Caligaris-Cappio, 2004). Viral infections are associ-
ated with transformation events in lymphomas, such as
Epstein-Barr virus associated lymphoproliferative dis-
orders (Rezk & Weiss, 2007) and some strains of Helico-
bacter pylori causing stomach maltomas and lympho-
mas. Treatment targeting the infection result in com-
plete remission in most of the cases, suggesting that
the lymphoproliferative disorder is driven by antigen
presentation originating from the infective mechanism
(Morgner et al., 2001). Activation of B cells using su-
pernatant of mast cells, identified the role of exosomes
as peptide presenting cells, resulting in blast formation,
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proliferation and IgM production, independent of cell-
to-cell interactions (Skokos et al., 2001). This supports
the role of antigens to stimulate, activate and transform
B cells, and prompted us to use exosomes as vehicles for
tumour derived antigen presentation in this study.
Of interest, CLL and mantle cell lymphomas are char-
acterised by a subset of B cells that express the CD5
marker (Dono, Cerruti & Zupo, 2004). CD5 positive B
cells constitute 80% of B cells in the human newborn de-
creasing to 10% of B cells in the adult human peripheral
blood (Dalloul, 2009). The CD5 molecule is mainly as-
sociated with a repressive signal (Soldevila, Raman &
Lozano, 2011), indicating that CD5 positive B cells are
under tight proliferative control.
Various studies indicate that B cell stereotypic sub-
sets (Damle et al., 2002; Stamatopoulos et al., 2007)
might emerge from the presentation of antigens. Our hy-
pothesis is that these stereotypic subsets might emerge
from co-occurrence with solid tumours and the antigenic
repertoire presented by apoptotic cancer cells. This is
supported by the fact that antibodies produced by CLL
cells can bind to cancer neoantigens from epidermoid
cells, melanoma and liver cancer antigens (Chu et al.,
2008, 2010) and that apoptotic cancer cells secrete exo-
somes (Fevrier & Raposo, 2004) into the microenvir-
onment eliciting an immune response (Delcayre, Shu &
Le Pecq, 2005). Immunogenic tumour-derived exosomes
potentially stimulate an indolent subset of immune cells,
resulting in transformation and clonal expansion as seen
in CLL. In addition studies have shown that CLL mAbs
recognize and bind the nonmuscle myosin heavy chain
IIA (MYHIIA) exposed on the cell surface of a subgroup
of apoptotic cells (MEAC) (Chu et al., 2008, 2010). In-
terestingly, 94% of CLL mAbs binding to MEACs ex-
pressed unmutated immunoglobulins, of which 88% be-
longed to a stereotyped subset.
In this study we identified a subset of B cells express-
ing low levels of CD5 and utilised cancer cell derived
exosomes to study the potential stimulation effect. Fur-
ther characterisation of these cells is required to allow
proper proliferation and expansion. The ultimate goal
of this study is to identify instigating carcinomatous
factors that may stimulate B1 cells to transform into
a CLL-like model.
2 Methods
2.1 Collection of material
50 adults and 20 neonatal blood samples were consen-
ted as per ethical approved project (University Research
ethics committee, University of Malta). The criteria for
selection of the senior citizens included the absence of
dementia and cancer. The serum samples were collected,
centrifuged and stored in the Malta Biobank together
with the consent forms. Mononuclear cells were isolated
from whole blood and stained accordingly for the flow
cytometry or the magnetic cell sorting as detailed below.
2.2 Flow Cytometry
A cohort of individuals (n = 50) over 65 years of age
were collected from Karen Grech Geriatric Wards. Fol-
lowing mononuclear cell isolation, the cells were in-
cubated with antibody mixes (from BD Biosciences)
consisting of fluorescein isothiocyanate (FITC) con-
jugated anti-CD5, PerCP-Cy5.5–conjugated anti-CD19,
FITC–anti-κ and phycoerythrin (PE)–anti-ń light chain.
At least 200,000 events were acquired on a FACS Calibur
equipped with a 488 argon ion laser and 635 red di-
ode laser (Becton Dickinson) and analysed with the
CellQuest software system (Becton Dickinson). The ra-
tio of κ+ and ń+ events was evaluated following gating of
CD19+ subsets. The κ/ń ratio was considered abnormal
when it was more than 3:1 or less than 1:3, providing
information on the monoclonal proliferation of CD19+
B lymphocytes.
2.3 Magnetic cell sorting (MACS)
For stimulation experiments, CD19+ cells from neonatal
whole blood were sorted using the EasySep Human
CD19 positive selection kit from Stem Cell Technolo-
gies, as per manufacturer’s instructions. In summary,
mononuclear cells were isolated using Ficoll Histopaque
(SIGMA), followed by addition of a positive selection
antibody cocktail. After mixing and incubation, the
magnetic nanoparticles were added. The cell suspen-
sion was placed into the magnet for 5 minutes and the
tube was inverted to remove the unbound cells. These
cells were labelled as CD19−. Following a number of
washes, cells were incubated overnight for subsequent
experiments.
2.4 Cytokine level measurements
The level of cytokines in serum were measured by a mul-
tiplexed method using a Procarta immunoassay (Affy-
metrix) on a Luminex platform. The serum and antigen
standards were prepared according to the protocol. The
captured protein was incubated with antibody conjug-
ated beads for 60 minutes. To detect the captured anti-
body conjugated beads these were incubated with biot-
inylated detection antibody for 30 minutes. The beads
were then incubated with streptavidin-SE (sape) for 30
minutes and the signal from the beads was read on the
Luminex instrument.
The filter plate was prepared, including standards,
samples and a blank. Antibody polystyrene beads were
added with antigen standards and serum samples. Fol-
lowing incubation at room temperature the plate was
mixed for 60 minutes at 700 rpm, washed and incub-
ated with the detection antbodies. Following addition
of SAPE and washes the fluorescence was read using the
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Luminex Analyser.
2.5 Exosome isolation
The prostate cancer cell line, PC3 and the epithelial
lung cancer cell line, A549 were cultured and expan-
ded to have at least 1× 108 cells. The cells were serum
deprived for 24 hours and 100 ml of supernatant was
harvested from each cell line.
Exosomes were isolated using an optimized protocol
kindly provided by Professor F. Cappello (University of
Palermo) (Merendino et al., 2010). The supernatant
was centrifuged at 2000 revs for 5 minutes to remove
the cells and cell debris, and transferred to ultracentri-
fuge tubes. Following a 2 hour spin at 110,000 g in a
ultracentrifuge (RotorT25) the resulting exosome pellet
was collected and suspended in 150 µl of PBS. The exo-
some suspension was stored at 4 ◦C until use. Figure 1
shows the resulting electron micrograph of the exosomes
isolated from the A549 cell line.
Figure 1: Electron micrograph showing exosomes isolated from
A549 cell line. The image was taken at Dipartimento di Bio-
medicina Sperimentale e Neuroscienze Cliniche, Sez. Anatomia
Umana, Universita` degli Studi di Palermo [Prof. Francesco Cap-
pello].
2.6 Stimulation experiments
The cells from the magnetic sorting preparation were
used for stimulation experiments. Both the CD19+ cells
and the CD19− cells were used in this experiment. Stim-
ulation was done using known lymphocyte stimulators,
Phytohemagglutinin (PHA) and Phrobolmyristate acet-
ate (PMA) or with exosome suspension isolated from
cancer cell lines. To remove macrophages, the cells were
incubated overnight and adherent cells were removed by
transferring suspension cells to a new culture flask. The
cells were divided into separate wells and treated with
a final concentration of 50 µg ml−1 PHA, 80 nm PMA,
and with exosome suspension derived from 2 cancer cell
lines (PC3: prostate cell lines; A549: lung cancer cell
lines), or left untreated. PHA was added to cells every
third day and exosomes once on day 1.
3 Results
3.1 Characterisation of a CD19+ CD5dim B
cells subset
The CD19+ fraction of the mononuclear cells derived
from neonate cord blood, was positive for CD5 (ROI 1;
Figure 2A). Of interest, the cells lacked a CD5 positive
(CD19−) T cell fraction. From a cohort of 50 senior
citizens, 25 samples were selected on the basis of the
number of CD19+ events (> 100 events). In addition to
the CD19+ B cells and the CD5+ T cells, immunopheno-
typing identified a CD19+ CD5dim fraction (Figure 2B).
The percentage of B cell subtypes in the cohort are sum-
marised in Table 1. In the age group between 65 and 75
years, less than 20% of total B cells (CD19+) stained for
CD5 (CD19+ CD5dim), while other age groups (n = 22)
showed samples with higher percentages (Figure 3). Of
interest, one of the senior citizens samples showed that
more than half (57.12%) of the B cells were typed as
Figure 2: Flow cytometry of stained (CD5 and CD19 antibodies)
mononuclear cells derived from (A) neonates and (B) adult (age
of 79). The quadrants in (A) were set using isotype controls. [ROI
1 = Region of Interest 1].
 
Figure 3 
 
 
 
   
Figure 3: Box plot showing distribution of CD19+ CD5dim per-
centage across age groups. Age group 65–75 (n = 3); age group
76–80 (n = 8); age group 81–85 (n = 7) and age group 86–90
(n = 7).
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Table 1: Percentage of B cell subtypes in the senior citizen cohort.
Sample Age CD5dim [CD19+ gated] CD5neg [CD19+ gated]
Events % of CD19+ Events % of CD19+
A8 87 381 57.12 285 42.73
A16 86 68 40.48 107 63.69
A22 77 68 32.85 168 81.16
A13 90 68 31.05 168 76.71
A21 76 41 30.15 88 64.71
A9 81 73 28.29 180 69.77
A49 79 141 22.56 362 57.92
A3 84 87 21.59 308 76.43
A32 80 39 20.42 140 73.3
A10 90 141 19.58 527 73.19
A42 73 28 17.72 120 75.95
A45 65 64 14.68 352 80.73
A39 87 20 14.39 118 84.89
A6 90 68 14.23 168 35.15
A11 76 50 13.16 289 76.05
A27 65 33 12.09 237 86.81
A14 84 11 10.68 80 77.67
A1 85 30 9.93 271 89.74
A38 85 11 9.91 90 81.08
A28 79 24 8.25 257 88.32
A50 78 39 7.93 377 76.63
A23 77 14 6.19 210 92.92
A44 89 9 3.93 210 91.7
A51 83 3 1.76 156 91.76
A19 83 3 0.95 313 98.74
Figure 4 
 
 
 
   
Figure 4: Distribution of IL6 and IL10 levels. The left
panel shows the results obtained for individuals which have a
CD19+/CD5dim: total CD19+ ratio higher than 0.2 (> 20% B1),
while the right panel individuals with a CD19+/CD5dim: total
CD19+ ratio lower than 0.05 (< 5% B1). [B1 = CD19+/CD5dim
cells].
CD19+ CD5dim. In this sample, flow cytometry using
ń/κ staining showed a monoclonal origin of the human
CD19+/CD5dim cells.
3.2 IL6 and IL10 levels are not affected by pres-
ence of CD19+ CD5dim cells
Given that the variance between age groups showed an
increase of CD19+/CD5dim cells with older age groups,
and that the age group between 65 and 75 were all below
20% of B cells (Figure 3), we used this as a threshold to
compare cytokine levels between those individuals with
a percentage higher than 20% and individuals in which
the CD19+/CD5dim cells are less than 5% of the total
B cells. Both IL6 and IL10 showed a high variance in
the different groups and although there is no significant
difference, the average of cytokine levels is higher in in-
dividuals having a CD19+/CD5dim: total CD19+ ratio
higher than 0.2 (> 20% B1; Figure 4).
3.3 Cancer cell line derived Exosomes stimulate
mononuclear cell expansion
The cord-blood derived CD19+ fraction, was cultured
in the various stimulants or left unstimulated. In ad-
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dition, the remaining fraction following separation was
also used in the experiment. The CD19+ fraction was
kept in culture only for 3 days and hence further exper-
iments were not possible. Hence, further experiments
require the isolation of this fraction from a monoclonal
lymphocytosis individual characterized in the screen-
ing described above. The other fraction was viable for
the whole duration of the experiment. The fraction
consisted of mononuclear cells with CD19+ cells deple-
tion. Proliferating cells under PHA stimulation were
confirmed to be CD5+, while cells under exosome stim-
ulation are not CD19+ or CD5+ (Figure 5A–5C). Infact,
electron microscopy show clearly that the proliferating
cells are larger and cytospins suggest selection for the
monocytic lineage. Of interest, at day 12 (Figure 5D–
5F) cells in the presence of exosomes show proliferation
of lymphocytes and monocytic cells. Proliferation of
lymphocytes was absent at day 12. Hence eventual ex-
periments should be designed to add exosomes at various
intervals. All cultures were stopped at day 21.F gure 5 
 
 
Figure 5: Flow cytometry of CD5/CD19 staining mononuclear
cells (A-C). A: Isotype control; B: PHA stimulated cells and C:
cells exposed to exosomes derived from PC3. Lower panel (D-F)
shows light microscopy images of D: unstimulated cells; E: PHA
stimulation at day 12; F: cells exposed to PC3-derived exosomes
at day 12.
4 Discussion
Previous studies show that the presence of CD5 positive
B cells increases with age in senior citizens (Geiger et al.,
2000); CD5 positive B cells are detected in human ma-
lignancies (Wang, Amato, Rabah, Zheng & Fernandes,
2002) and that the presence of CD5 positive B cells in re-
latives of Chronic lymphocytic leukemia (CLL) patients,
increases the risk of acquiring the disease (Rawstron et
al., 2002). This suggests that these cells are potential
precursors that require a transformation event, to pro-
gress into a malignant phenotype. To study transforma-
tion to malignant phenotype, a source of physiologically
occurring CD5 positive cells is required. CD5 express-
ing B cells include (1) the life-long pool of B1 cells hom-
ing primarily to the peritoneal cavity, and having the
capacity of self renewal; (2) the CD5+ B cell subpopu-
lation in neonatal blood (Erkeller-Yuksel et al., 1992);
and (3) monoclonal lymphocytosis in the elderly (Ghia
et al., 2004). Hence we decided to immunophenotype
cord blood and a cohort of senior citizens. Of interest
all CD19+ cells in neonatal derived lymphocytes highly
express the CD5+ marker. In addition we show the pres-
ence of a subset of CD19+ B cells with low expression of
CD5, CD19+/CD5dim. The percent of CD19+/CD5dim
to total CD19+ increases with age (Figure 3), with per-
centages higher than 40% found in 2 individuals over 80
years of age. Weak expression of CD5 in CD19+ B cells
were previously described in a patient cohort of CLLs
(Wang et al., 2002), showing heterogeneity of CD5 ex-
pression levels. The significance of the differential level
of CD5 expression in B cells is unknown, and hence un-
derstanding their origin and function towards initiation
or development of B cell malignancy is imperative.
Survival of CD5 expressing B cells depends on CD5-
dependent IL10 production (Gary-Gouy et al., 2002). In
addition to B1 cells, a subset of CD5 positive B cells pro-
duce IL10 and have a regulatory function (Yanaba et al.,
2008). Although the CD19+/CD5dim cells characterised
in this study have a low expression of CD5, we meas-
ured the level of IL10 and other cytokines in the sera of
senior citizens. As shown in Figure 4, the IL10 level var-
ies considerable, but there is a trend to a higher mean
level of IL10 in elderly with higher proportion (percent
of total B cells) of CD19+/CD5dim cells. IL6 was selec-
ted for analysis since with increasing age, this cytokine is
more abundant and provides an inflammatory response
required for the formation of various cell clones and in
the transformation of the benign condition, MGUS into
Multiple Myeloma (Fayad et al., 2001). Our interest
is that IL6 might also be involved in the transforma-
tion of MBL into a malignant CLL condition. Further
analysis is required to quantify IL10 release in sorted
cells. Of interest, the stimulation of B cells with phor-
bolmyristic acetate (PMA), increases the expression of
CD5 (Youinou, Mackenzie, Jouquan, Le Goff & Lydy-
ard, 1987). This suggests that cells can acquire the ex-
pression of CD5 through an activation stimulus. In this
study we used neonatal-sorted CD19+ CD5+ cells to
address the potential activation of CD5 positive B cells
using well known activators, such as PMA, and cancer
cell- derived exosomes as a vehicle to present cancer an-
tigens. In the stimulation experiment, we used both pos-
itively selected CD19+ cells and the mononuclear cells
depleted of CD19+ cells, derived from neonatal blood.
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The positive selected CD19+ cells lost viability after 3
days, and the stimulation experiment was performed us-
ing the cells depleted of CD19+ cells (CD19− fraction).
In comparison with PHA and PMA (known lympho-
cyte stimulators), the exosomes isolated from 2 cancer
cells lines, A549 (lung epithelial) and PC3 (prostate cell
line) stimulated the proliferation of monocytic-like cells.
Characterization is required to know the origin of these
cells and further studies should utilise CD19+/CD5dim
cells from elderly individuals, ideally from the 2 indi-
viduals that have a high percentage of cells expressing
the CD5 marker.
5 Conclusion
Creating a cellular model of B cell transformation fol-
lowing antigen presentation will provide a tool to study
the origin of CD5 positive cells and to understand the
role of tumour derived-exosomes in antigen presentation
and activation of B cells. In this paper we show the pres-
ence of a specific population of CD5 positive cells that
re-emerge in the elderly individuals, and the capacity
of tumour derived exosomes to stimulate lymphocytes
and monocyte-like cells. Further studies are required to
expand the CD19+ CD5+ cells. Understanding stimu-
lation and proliferation of these cells will be useful as a
CLL-like model.
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